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We have previously shown that expression of the
transcription factor ARNT/HIF1b is reduced in islets
of humans with type 2 diabetes. We have now found
that ARNT is also reduced in livers of diabetics. To
study the functional effect of its reduction, we
created mice with liver-specific ablation (L-ARNT
KO) using ARNT loxP mice and adenoviral-mediated
delivery of Cre. L-ARNT KO mice had normal blood
glucose but increased fed insulin levels. These
mice also exhibited features of type 2 diabetes with
increased hepatic gluconeogenesis, increased lipo-
genic gene expression, and low serum b-hydroxybu-
tyrate. These effects appear to be secondary to
increased expression of CCAAT/enhancer-binding
protein alpha (C/EBPa), farnesoid X receptor (FXR),
and sterol response element-binding protein 1c
(SREBP-1c) and a reduction in phosphorylation of
AMPKwithout changes in the expression of enzymes
in ketogenesis, fatty acid oxidation, or FGF21. These
results demonstrate that a deficiency of ARNT action
in the liver, coupled with that in b cells, could
contribute to the metabolic phenotype of human
type 2 diabetes.
INTRODUCTION
The liver plays a major role in glucose and lipid homeostasis in
both humans and rodents (Saltiel and Kahn, 2001; Michael
et al., 2000). Hepatic glucose production is critical in the fasting
state, providing fuel for the brain, renal medulla, and red blood
cells. Initially, hepatic glucose is released from glycogen by the
process of glycogenolysis, but after several hours of fasting,
glucose production is primarily from gluconeogenesis, a process
by which the liver produces glucose from precursors such as
lactate and pyruvate (Pilkis and Granner, 1992; Cherrington
et al., 1998). In addition, fatty acid b-oxidation is activated during
fasting, providing ATP for the liver (Postic et al., 2004) and gener-428 Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc.ating ketone bodies, which provide an alternative fuel source for
the brain and heart (Blazquez et al., 1999). Gluconeogenesis,
fatty acid b-oxidation, and ketogenesis are all suppressed by
insulin. In pathological states, such as type 1 diabetes mellitus,
elevated gluconeogenesis and ketogenesis contribute signifi-
cantly to hyperglycemia and hyperketonemia. One unexplained
and interesting finding is that in type 2 diabetes, where insulin
resistance predominates, gluconeogenesis is increased without
an obvious increase in ketogenesis (Cherrington et al., 1998).
Multiple transcription factors and coregulators have been
identified as the downstream targets of insulin signaling in the
regulation of gluconeogenesis, lipogenesis, and fatty acid oxida-
tion in the liver, including the peroxisome proliferator-activated
receptors (PPARs), the PPAR coactivators PGC-1a and
PGC-1b, forkhead box O1 (FoxO1), farnesoid X receptor (FXR),
sterol response element-binding protein 1c (SREBP-1c), and
CCAAT/enhancer-binding proteins (C/EBPs) (Pedersen et al.,
2007; Qiao et al., 2006; Sinal et al., 2000; Foufelle and Ferre,
2002; Horton et al., 2002; Puigserver et al., 2003; Yoon et al.,
2001). These proteins function either cooperatively or in parallel
in the regulation of expression of genes in glucose and lipid
metabolism. To date, the upstream regulators of the key tran-
scription factors involved in control of glucose, lipid, and ketone
homeostasis in the diabetic state remain largely unknown.
The aryl hydrocarbon receptor nuclear translocator (ARNT),
also known as hypoxia-inducible factor 1b (HIF1b), is a ubiqui-
tously expressed nuclear protein that belongs to the basic
helix-loop-helix (bHLH)/PAS family of transcription factors (Reisz-
Porszasz et al., 1994). ARNT is a heterodimerization partner for
several members of the bHLH transcription factor family. The
most extensively studied include the aryl hydrocarbon receptor
(AHR), which responds to exogenous organic molecules, such
as dioxins; and HIF1a, which is regulated by cellular oxygen
tension (Semenza, 1999; Ema et al., 1997). With its cognate het-
erodimer partners, ARNT regulates a wide range of processes
involving detoxification of organic molecules, response to
hypoxia, development of the vascular system, cell proliferation,
and control of glycolytic enzymes (Semenza, 1999; Ema et al.,
1997).
Previous studies from our laboratory have demonstrated
reduced expression of ARNT in b cells in humans with type 2 dia-
betes and provided evidence that this reduction contributes to
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Function of ARNT in Liverimpaired insulin secretion in type 2 diabetes (Gunton et al., 2005).
In the present study, we found that ARNT expression was also
reduced in liver of obese individuals with type 2 diabetes. We
further demonstrated that liver-specific knockout of the ARNT/
HIF1b increases the expression of key lipogenic and gluconeo-
genic enzymes, resulting in increased gluconeogenesis and
dyslipidemia but low levels of circulatory ketones. Such effects
appear to be mediated by activation of key transcription factors
in gluconeogenesis and lipogenesis, including SREBP-1c, FXR,
and C/EBPa. Together, these results suggest that ARNT plays
important roles in the control of metabolism in b cells and liver,
and that alterations in ARNT expression in liver may lead to
dysregulation of glucose homeostasis and lipid metabolism
without increased ketogenesis.
RESULTS
Reduced Expression of ARNT in the Livers
of Humans with Type 2 Diabetes and Mice
with STZ-Induced Diabetes
Microarray analysis was performed to assess expression of
ARNT in liver specimens from normal lean individuals, obese
individuals, and obese type 2 diabetics. Expression of ARNT
mRNA was not altered in obese subjects without diabetes
mellitus (DM), but was reduced in obese type 2 diabetic patients
with both well-controlled (DM [W]) and poorly-controlled (DM [P])
blood glucose levels (Figure 1A). Although these differences did
not reach statistical significance in each diabetic group due to
the small sample size, when considered together, the data
demonstrated an average 30% decrease in the expression of
ARNTmRNA in the liver of obese individuals with type 2 diabetes
(p < 0.02). As shown in Table 1, blood glucose concentrations
and fasting insulin levels were higher in the DM (W) and DM (P)
groups compared to the lean controls (p < 0.05). Thus, high
glucose levels, high insulin levels, and insulin resistance are
associated with the reduced expression of ARNT in the livers
of humans with type 2 diabetes.
To determine the effects of insulin and glucose in the regulation
ofARNT, streptozocin (STZ)-induceddiabeticmicewere studied.
Theglucose levels in thesemicewereelevated4-fold over control
(564 ± 9.8 versus 139 ± 7.8 mg/dl, p < 0.005), while insulin levels
were almost undetectable. Expression of ARNT protein in STZ
diabetic mice was reduced to 63% ± 9% of Control levels (p <
0.004), and this was largely restored to baseline upon insulin
treatment (Figure 1B), suggesting that insulin signaling activates
the expression of the ARNT gene and that ARNT expression is
reduced in both insulin-deficient and insulin-resistant states.
Insulin, but Not Glucose, Increases the Expression
and Nuclear Translocation of ARNT
To determine whether the regulation of ARNT expression is
a direct effect of glucose or insulin, human hepatoblastoma
Huh7 cells were exposed for 16 hr to either low (5 mM) or high
(25 mM) glucose and 0, 10, or 100 nM insulin and analyzed for
ARNT expression by western blotting. No changes in the expres-
sion of ARNT were observed at the different glucose concentra-
tions (Figure 1C); however, pretreatment for 16 hr with insulin at
10 and 100 nM increased the expression of ARNT protein to
120% and 130% of Control, respectively (Figure 1D, p < 0.05).To further determine whether subcellular distribution of ARNT
protein is regulated by glucose or insulin, Huh7 cells were
exposed for 5min to D-glucose (dextrose) at different concentra-
tions, 22 mM L-glucose, or 100 nM insulin. Neither D- nor
L-glucose changed nuclear translocation of ARNT protein
(Figure 1E). However, when Huh7 cells were treated with insulin
for 5 min and then subjected to fraction, there was a clear trans-
location of ARNT protein from the cytoplasm to the nuclear frac-
tion (Figure 1E). Insulin-induced ARNT nuclear translocation was
also observed by immunofluorescent staining. Thus, in the basal
state, ARNT protein wasmainly located in the cytoplasm of Huh7
cells (Figure 1F, subpanels a and c). When these cells were
treated with insulin at 10 and 100 nM (Figure 1F, subpanels c
and d) individually for 5 min, ARNT protein translocated into
the nucleus. Thus, insulin can increase the expression and the
nuclear translocation of ARNT protein in liver. By contrast,
glucose does not directly regulate the expression or nuclear
translocation of ARNT.
Acute Ablation of ARNT in Mouse Liver (L-ARNT KO)
To define the potential effects of reduced ARNT expression in the
liver, we created an acute postnatal liver-specific ablation of
ARNT by tail-vein injection of an adenovirus carrying Cre recom-
binase (Ad-Cre) into mice carrying two copies of the ARNT gene
inwhich exon 6was flanked by loxP sites (flox/floxmice) to create
the L-ARNT KO mouse (Tomita et al., 2000). Same age and sex
ARNT flox/flox mice were injected with Ad-CMV vector as
controls (Control). Three independent groups of five or six pairs
of mice (age 9–11 months) were studied between days 4 and 6
after the adenoviral injection to determine the effect of acute
ARNT deletion on metabolism and gene and protein expression.
One was a group of six pairs of female mice on normal chow diet
(FNC). The second group consisted of five pairs of male mice on
normal chow diet (MNC). The third group represents six pairs of
female mice on high-fat (60%) diet for 3 months (FHF).
To determine the efficacy of Ad-Cre recombination of the
ARNT gene, real-time RT-PCR was performed to quantify
ARNT mRNA in liver of all three groups of mice 6 days after
adenovirus injection, using TBP mRNA as the normalization
control. Expression of ARNT mRNA was reduced to 37% ± 5%
of control levels in the liver of the FNC group (Figure 2A) and to
26% ± 3% and 24% ± 4% of Control in the liver of the MNC
and FHF mice (p < 0.00005). Consistent with the mRNA results,
expression of ARNT protein was undetectable by western blot
of livers of L-ARNT KO mice from the FNC group (Figure 2B), as
well as in the livers of MNC and FHF mice.
L-ARNT KO Induces Insulin Secretion
and Hepatic Gluconeogenesis
When compared to levels prior to initiation of the experiment,
there were slight reductions in body weight and food intake in
both L-ARNT KO and Control mice after adenovirus injection.
However, there were no significant differences in body weight
or food intake between L-ARNT KO and Control mice in any of
the three groups (Figure S1A) on day 6 after the adenovirus injec-
tion; there was no difference in blood glucose levels between
L-ARNTKOmice andControl in either of the FNC orMNCgroups
on normal chow (Figure 2C). However, a small but statistically
significant increase in fed blood glucose levels was observedCell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc. 429
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Function of ARNT in LiverFigure 1. Regulation of ARNT Expression in the Liver of Human and Mouse Models of Diabetes
(A) Microarray analysis of ARNT expression in the individuals with lean body mass, obesity, and type 2 diabetes with well-controlled and/or poorly controlled
blood glucose levels. Gene expression data were normalized with U133A Affymetrix internal gene expression parameters. The ARNT probe set is 218221_at
on human genome U133A array. DM (W) and DM (P) represent type 2 diabetes with well-controlled and poorly controlled glucose, respectively. DM (W + P)
presents the pooled results of DM (W) and DM (P). Data are means ± SEM of values from each group. Asterisks indicate p < 0.02.
(B) Expression of ARNT protein in the livers of STZ-induced male diabetic mice with or without insulin administration. Protein extracts from liver samples were
analyzed by immunoblotting for ARNT as described in the Experimental Procedures. Each lane represents the liver protein extract from an individual mouse. Data
are means ± SEM of values from four or five mice. Asterisks indicate p = 0.004.
(C) Effect of glucose on the expression of ARNT. Human hepatoblastoma (Huh7) cells were treated with 5 mM and 25 mM glucose for 16 hr, and extracts were
western blotted for ARNT as described in the Experimental Procedures. Data are means ± SEM of values from three experiments.
(D) Effect of insulin on the expression of ARNT. Huh7 cells were treated with 10 nM and 100 nM insulin for 16 hr. Data are means ± SEM of values from four
experiments. Asterisks indicate p < 0.05.
(E) Effect of glucose and insulin on nuclear localization of ARNT. Huh7 cells were treated with glucose at 0 mM, 5 mM, 11 mM, and 22 mM; 22 mM L-glucose; or
100 nM insulin for 5 min. Protein extracts from nucleus and cytoplasm fractions of these cells were isolated and analyzed by immunoblotting for ARNT as
described in the Experimental Procedures. Data are representative of 3–5 independent experiments.
(F) Effect of insulin on ARNT subcellular translocation. Huh7 cells were incubated with 10 nMand 100 nM insulin for 5min. Theywere then fixed and incubatedwith
an antibody against ARNT at 4C for 24 hr andwere subsequently blotted with GFP-conjugated IgG (Jackson Laboratory) for 1 hr at room temperature in the dark.
The cells were evaluated using fluorescent microscopes. Subpanels (a) and (b) represent cells treated with 0 nM and 10 nM insulin, respectively. Subpanels (c)
and (d) represent cells treated with 0 nM and 100 nM insulin. Data are representative of three independent experiments.430 Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc.
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Function of ARNT in LiverTable 1. Clinical and Biochemical Data Obtained from Individuals with Lean Body Mass, Obesity, and Type 2 Diabetes with Both
Well-Controlled and Poorly Controlled Blood Glucose Levels
Lean Control Obese
Obese DM Well
Controlled (DM [W])
Obese DM Poorly
Controlled (DM [P])
Subjects per group 5 4 7 4
Age (years) 36 ± 12 39 ± 11 45 ± 12 43 ± 14
Gender 5 F 1 M / 3 F 2 M / 5 F 2 M / 2 F
BMI (kg/m2) 24 ± 5 52 ± 4a 53 ± 9a 55 ± 4a
Fasting glucose (mg/dl) 86 ± 14 88 ± 9 135 ± 35a 211 ± 87
Fasting insulin (mU/ml) 6.3 ± 5.6 21.7 ± 20.8 25.0 ± 20.3 72.9 ± 48.6
HOMA-IR 1.5 ± 1.4 5.0 ± 5.4 8.5 ± 7.4 38.5 ± 31.9
SI (insulin sensitivity) 0.9 ± 1.5 0.8 ± 0.9 0.1 ± 0.2
Hemoglobin A1C (%) 5.4 ± 0.3 5.2 ± 0.1 6.3 ± 0.6a 9.9 ± 1.1a
Liver lipid (% of area) 2.4 ± 3.1 9.8 ± 17.6 15.2 ± 13.2 9.3 ± 4.9
Clinical and biochemical data obtained from individuals with lean body mass, obesity, and type 2 diabetes with both well-controlled and poorly
controlled blood glucose levels. Human liver samples were obtained from volunteers undergoing elective cholecystectomy (lean subjects) and gastric
bypass surgery (morbidly obese with or without type 2 diabetes).
a Indicates p < 0.05 compared with lean control.in L-ARNT KO mice from the FHF group compared with Control
(127.6 ± 5.0 mg/dl versus 106.4 ± 7.6 mg/dl; p < 0.05)
(Figure 2C). Fed insulin levels of Control and L-ARNT KO mice
were 0.25 ± 0.05 ng/dl versus 0.48 ± 0.14 ng/dl in the FNC group
and 1.51 ± 0.77 ng/dl versus 3.30 ± 1.14 ng/dl in the MNC group
and were significantly increased from 0.62 ± 0.11 ng/dl to 1.20 ±
0.20 ng/dl in the FHF group (p = 0.04) (Figure 2D). Increased
fed insulin levels with normal to higher blood glucose levels in
the L-ARNT KO mice were observed in each of the three inde-
pendent experimental groups.
To better assess the effect of L-ARNT KO on the whole-body
glucose utilization, intraperitoneal glucose tolerance tests (GTTs)
were performed in the FNC, FHF, and MNC groups (Figure 2E).
Integrated glucose concentrations were calculated as the area
under the curve (AUC). Overall, no significant differences in the
AUC were observed in either the FNC or FHF groups
(Figure S1B). Thus, the higher serum insulin levels were able to
compensate for the insulin resistance in female L-ARNT KO
mice. GTT tests in L-ARNT KO mice from the MNC group, on
the other hand, revealed a significant increase in glucose values
at all points from 15 to 120 min (Figure 2E).
To directly examine the effect of deficiency of ARNT on hepatic
glucose output, pyruvate challenge experimentswere performed
using the FHF and MNC groups. By measuring blood glucose in
response to the administration of pyruvate, a major gluconeo-
genic substrate, one gets an estimation of gluconeogenic poten-
tial in vivo. Followingpyruvate administration inControlmice from
the FHF group, blood glucose concentrations increased by
46 mg/dl over basal levels at 15 min (p < 0.005), plateaued, and
then decreased after 60 min. Glucose concentrations in L-
ARNT KO mice were higher at all time points: 138 ± 9.5 mg/dl
versus 107 ± 4.5 mg/dl at 15 min (p = 0.02), 120.7 ± 6.2 mg/dl
versus 85.6 ± 8.1 mg/dl at 30 min (p = 0.01), and 66.2 ± 7.2 mg/
dl versus 48 ± 6.7 mg/dl at 60 min (p = 0.10) (Figure 2F). The
area under the serum glucose curve following the pyruvate chal-
lenge in the FHF group of L-ARNT KO mice was increased 34%
compared to theControl (p < 0.02) (Figure 2G). In theMNCgroup,
glucose concentrations in L-ARNT KO versus Control mice werealso higher by 40%–50% at the 15, 50, and 60 min time points
(p = 0.06, 0.01, and 0.05, respectively) (Figure 2F). The AUC in
the MNC group of L-ARNT KO mice was also increased by
41% (p < 0.05) (Figure 2G). Taken together, these results indicate
L-ARNT KO mice have significantly increased ability to convert
pyruvate to glucose, i.e., higher hepatic gluconeogenesis, than
normal mice.
Insulin Sensitivity and Hepatic Glucose Production
by Hyperinsulinemic-Euglycemic Clamp
To measure more precisely whole-body insulin sensitivity and
hepatic glucose production, we performed hyperinsulinemic-
euglycemic clamps with D-[3-3H]glucose in the FNC group. At
the time of this procedure, there was no significant difference in
body weight (40.3 ± 2.1 g versus 38.7 ± 1.9 g) or fasting glucose
levels (104 ± 5 mg/dl versus 106 ± 1 mg/dl) between the Control
andL-ARNTKOmice.Whole-body insulin sensitivity, asquantified
by the glucose infusion rate during the hyperinsulinemic-
euglycemic clamp, was reduced in the L-ARNT KO mice (n = 5)
to 22.9 ± 2.8 mg/kg/min, compared with 27.2 ± 4.5 mg/kg/min in
theControls (n = 6), suggestingmildwhole-body insulin resistance
(Figure 2H). Interestingly, basal hepatic glucose production was
also increased in the L-ARNT KO mice, from 53 ± 12 mg/kg/min
to 72 ± 21 mg/kg/min (Figure 2I). Although this difference did not
quite reach statistical significance, when considered along with
the increased response to the pyruvate challenge, this finding
is consistent with increased basal gluconeogenesis in the
L-ARNTKOmice.During thehyperinsulinemic-euglycemicclamp,
insulin suppressedhepatic glucoseproduction inboth theL-ARNT
and Control groups to a similar extent (82%± 6.2% versus 71%±
7.3%) (Figure 2I).
Potential Mechanisms of Increased Hepatic
Gluconeogenesis in L-ARNT KO Mice
To determine the mechanisms of increased hepatic gluconeo-
genesis caused by L-ARNT KO, the mRNA expression levels of
key gluconeogenic enzymes, including phosphoenolpyruvate
carboxykinase (PEPCK), fructose 1,6-bisphosphatase (FBP1),Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc. 431
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Function of ARNT in LiverFigure 2. Glucose Metabolism in the Mice with Acute Liver-Specific Ablation of ARNT
(A) The ARNT flox/flox mice were injected via the tail vein with adenovirus Ad-Cre vector to knock out ARNT in liver (L-ARNT KO). Age- and sex-matched ARNT
flox/flox mice were injected with Ad-CMV as controls (Control). Six days after injection, hepatic mRNA levels of ARNT were measured by real-time RT-PCR.
(B) ARNT protein levels were measured from a 30 mg aliquot of total homogenates from liver by western blot analysis. Each lane represents the liver sample from
an individual mouse.
(C and D) Fed blood glucose and insulin levels were measured in Control and L-ARNT KO mice from the FNC, FHF, and MNC groups.
(E) Glucose tolerance tests (GTTs) were performed in Control and L-ARNT KO mice from the FNC, FHF, and MNC groups.
(F) Pyruvate challenge tests in Control and L-ARNT KO mice from the FHF and MNC groups were used to assess hepatic gluconeogenesis.
(G) The area under the curve (AUC) for serum glucose during the pyruvate challenge tests from FHF andMNC groups were calculated using the linear trapezoidal
rule, subtracting the baseline value from each time point.
(H) Glucose infusion rates for Control and L-ARNT KO mice from the FNC group during the euglycemic clamp were measured.432 Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc.
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Function of ARNT in LiverFigure 3. Effect of L-ARNT KO on the Expression of Hepatic Gluconeogenic Enzymes
(A) mRNA levels of gluconeogenic genes from the livers of the three experimental groupsweremeasured by real-time RT-PCR. The livers of mice from each group
were obtained in the fed stage at day 6 after injection. Data are representative of results obtained from five or six mice in each group.
(B) mRNA levels of transcription factors and coactivators involved in the regulation of PEPCK, G6Pase, and FBP1 were measured by real-time PCR. Data are
representative of results obtained from six mice in the FNC group.
(C) C/EBPa protein level wasmeasured by immunoblotting in the livers of L-ARNTKOmice from the FNCgroup. Each lane represents the liver protein extract from
an individual mouse. Quantification data of C/EBPa protein were obtained from five mice. Asterisks indicate p < 0.05.and glucose 6-phosphatase (G6Pase), were measured in fed
Control and L-ARNTKOmice. As shown in Figure 3A, expression
levels of PEPCK andG6PasemRNAswere increased 3- to 5-fold
and 1.5- to 3-fold in the livers of L-ARNT KOmice compared with
fed Control in each of the three experimental groups (Figure 3A).
The expression level of FBP1 mRNA was also significantly
increased in the livers of L-ARNT KO mice from both the FNC
andMNCgroups,but not from theFHFgroup.Thus, the increased
hepatic gluconeogenesis in L-ARNT KO mice was the result of
increased expression of key gluconeogenic enzymes.
It is known that many transcription factors and coactivators,
including hepatocyte nuclear factor a (HNF-4a), FoxA2/HNF-3b,
FoxO1, PGC-1a, CREB, and C/EBPa, are involved in the regula-
tion of the PEPCK gene (Roesler et al., 1989; Pilkis and Granner,1992; Yoon et al., 2001). Many of these transcription factors and
coregulators are also involved in the regulationof other keygluco-
neogenic enzymes, suchasG6Pase (Schmoll et al., 1999;Onuma
et al., 2006). To determine whether ARNT regulates the expres-
sion of the gluconeogenic enzymes through the regulation of
these key transcription factors, expression of genes encoding
these factors was studied in the liver samples of L-ARNT KO
and control mice under fed conditions. No significant differences
were found in the expression of mRNA levels of CREB, FoxA2,
FoxO1, HNF-4a, PGC-1a, and PGC-1b genes in the livers of the
L-ARNT KOmice from the FNC group (Figures 3B). Interestingly,
there was a two-fold induction of C/EBPa mRNA, but not the
expression of C/EBPb and C/EBPd, in the livers of L-ARNT KO
mice, and this was paralleled by a 2-fold increase in C/EBPa(I) Basal and insulin-suppressed hepatic glucose production in Control and L-ARNT KO mice from the FNC group were measured during the euglycemic clamp.
The black line with black boxes in the figure represents the data obtained from L-ARNT KOmice. The dotted line with open boxes in the figure represents the data
obtained from Control mice. Data are means ± SEM of values from five or six mice. Asterisks indicate p < 0.05. Data from Figures 2C–2I are means ± SEM of
values from five or six mice. Asterisks indicate p < 0.05.Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc. 433
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Function of ARNT in Liverprotein (Figure 3C). Similar results were observed in the MNC
group (Figure S2). The possibility that the L-ARNT KO activates
gluconeogenesis through activation of the expression of C/
EBPa gene is consistent with the growing body of literature
showing that C/EBPa is involved in the regulation of gluconeo-
genesis and lipid metabolism in the liver (Pedersen et al., 2007;
Qiao et al., 2006).
L-ARNT KO Increases Hepatic Lipogenesis but Reduces
Hepatic Lipid Storage
To determine the effect of L-ARNT KO on lipid metabolism,
concentrations of cholesterol, triglyceride (TG), and free fatty
acids (FFA) were measured in the serum of L-ARNT KO mice
from each experimental group 6 days after the adenovirus
injection (Figure 4A). No significant changes were observed in
fed cholesterol levels in L-ARNT KO mice from each group
compared with Control (Figure 4A). Fed TG concentrations in
the serum of L-ARNT KO mice from the FHF group were signifi-
cantly reduced compared with Control (p < 0.01). Fed serum FFA
levels of L-ARNT KO mice versus Control from the FNC group
were also significantly reduced (p < 0.004). A trend for a similar
reduction of fed FFA concentration was seen in L-ARNT KO
mice from the FHF group. Fasting FFA concentrations in
L-ARNT KO mice from the MNC group were also significantly
reduced compared with Control (p < 0.05) (Figure 4B).
We further determined the effect of L-ARNT KO on hepatic
lipid metabolism by assessing hepatic lipid content and lipid
distribution. Total liver TG content was reduced by 50% in
the MNC group but not in the FNC group (Figure 4C). When
de vivo hepatic fatty acid and TG synthesis weremeasured using
tritiated water, there were no significant differences between
L-ARNTKOmice andControl (Figure 4D). Interestingly, however,
on oil red O staining (Figure 4E), the lipid droplets in the livers
of L-ARNT KO mice from both the FNC and MNC groups were
noticeably smaller when compared with the lipid droplets in
the Control. Thus, ARNT deletion converts fat storage from
a macrovesicular pattern to a microvesicular pattern. It is known
that the PAT family proteins (perilipin, adipose differentiation-
related protein [ADRP], and tail-interacting protein of 47 kDa
[TIP47]) contribute to formation and function of lipid storage
droplets (Londos et al., 2005). ADRP and TIP47 were expressed
abundantly in liver. Gene expression analysis revealed a trend
toward reduction of ADRP gene in the livers of both male and
female L-ARNT KO mice compared to Control, but neither of
these changes reached statistical significance (Figure S3).
Alterations in Genes Controlling Hepatic Lipogenesis
in the L-ARNT KO Mice
Changes in serum lipid levels and hepatic lipids were secondary
to changes in genes and transcriptional regulators of hepatic
lipogenesis. Thus, the expression of SCD1 and FAS mRNAs in
the livers of fed L-ARNT KO mice were increased 2- to 7-fold
compared with Control in each of the three groups (Figure 4F).
Similarly, the expression of FAS protein in the livers of L-ARNT
KO mice from the MNC group was also increased 1.5-fold
(Figure 4G). On the other hand, there were no significant differ-
ences in the expression of the genes encoding transcription
factors involved in the regulation of hepatic lipogenesis,
including LXR, PPARa, PPARg, and SREBP-1a, in the livers of434 Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc.L-ARNT KO mice of either the FNC (Figure 4H) or MNC group
(data not shown). However, therewas a 2-fold induction in the ex-
pression of SREBP-1c and FXR genes in the livers of L-ARNT KO
mice fromboth of these groups (Figure 4H and Figure S2), aswell
as the 2-fold increase in C/EBPa shown above. The SREBP-1c
protein is synthesized in endoplasmic reticulum and further
processed in the Golgi apparatus, where proteases liberate the
N-terminal mature forms that translocate to the nucleus to acti-
vate lipogenic genes. The level of mature forms of SREBP-1c
protein was significantly increased in the hepatic nuclear extract
of L-ARNT KO mice from the MNC group (Figure 4I). Thus, three
transcription factors (FXR, SREBP-1c, and C/EBPa) involved in
the regulation of hepatic lipogenesis (Pedersen et al., 2007;
Qiao et al., 2006; Sinal et al., 2000; Foufelle and Ferre, 2002;
Horton et al., 2002; Puigserver et al., 2003) are increased in the
L-ARNT KO mice and could contribute to the increased hepatic
lipogenesis.
L-ARNT KO Reduces Serum b-Hydroxybutyrate Levels
Ketone bodies, including b-hydroxybutyrate (b-OHB), are mainly
generated in liver from serum FFA as a result of b-oxidation and
ketogenesis (Blazquez et al., 1999). Despite similar food intake,
L-ARNT KO mice exhibit significantly decreased fed serum
b-OHB levels. In the FNC group, fed b-OHB levels from
L-ARNT KO mice versus Control were 0.64 ± 0.05 mM versus
0.37 ± 0.07 mM (p = 0.01). In the FHF and MNC groups, fed
serum b-OHB levels from L-ARNT KO mice were lower than in
Controls; however, they did not reach significance due to the
large variation (Figure 5A). Under fasting conditions, however,
serum b-OHB levels from the MNC group of L-ARNT KO mice
were significantly lower than Control (Figure 5B). Interestingly,
these changes in serum ketone levels in the L-ARNT KO mice
occurred with no significant alteration in expression of genes en-
coding key enzymes in fatty acid b-oxidation or hepatic ketogen-
esis (Figure S4 and Table S1).
AMP-activated protein kinase (AMPK) plays a regulatory role
in the control of fatty acid b-oxidation. Phosphorylation of
AMPK activates fatty acid b-oxidation through phosphorylation
of ACC1 (Blazquez et al., 1999; Ruderman et al., 2003; Musi,
2006; Assifi et al., 2005).Western blot analysis revealed no differ-
ences in expression of AMPK protein in the livers of L-ARNT KO
mice compared with fed Control in both the FNC and MNC
groups (Figure 5C). Interestingly, there was a 40% reduction of
phosphorylated AMPK (p-AMPK) in livers of male L-ARNT KO
mice and a 20% reduction of p-AMPK from the FNC group
(Figures 5C and 5D). However, this was not accompanied by
a change in phosphorylation status of ACC1, a marker of
AMPK activity (Figure 5C).
Malonyl-CoA inhibits fatty acid b-oxidation by inhibition of
Carnitine Palmitoyltransferase I (CPT-I) activity (McGarry et al.,
1983; Ruderman et al., 2003). To determine whether L-ARNT
KO affects hepatic malonyl-CoA production, liver extracts from
both L-ARNT KO mice and Control mice were measured radio-
enzymatically. Malonyl-CoA levels were slightly increased in
the livers of L-ARNT KO mice from both the FNC and MNC
groups compared with Control; however, these did not reach
statistical significance (Figure 4E). While modest, the reduced
p-AMPK and slightly increased malonyl-CoA levels may account
for the reduction of serum b-OHB levels.
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Function of ARNT in LiverFigure 4. Effect of L-ARNT KO on Hepatic Lipid Metabolism
(A) Serum cholesterol, triglyceride (TG), and FFA levels in Control and L-ARNT KO mice from the FNC, FHF, and MNC groups in the fed condition.
(B) Fasting serum FFA level in Control and L-ARNT KO mice from the MNC group.
(C) Liver TG levels in Control and L-ARNT KO mice from the FNC and MNC groups.
(D) Fatty acid and TG synthesis in the livers of Control and L-ARNT KOmice from the MNC group. Data from Figures 4A–4D are representative of results obtained
from five or six mice in each group. Asterisks indicate p < 0.05.
(E) Oil red O staining of liver slides of Control and L-ARNTKOmice from the FNC andMNCgroups. Data are representative of five or six independent experiments.
(F) mRNA levels of lipogenic genes in the livers of Control and L-ARNT KO mice from the FNC, MNC, and FHF groups under the fasting condition.
(G) Protein levels of ACC1 and FAS were measured by western blot in the livers of Control and L-ARNT KO mice from the FNC group.
(H) mRNA levels of transcription factors and coactivators involved in the regulation of lipogenic genes in the livers of Control and L-ARNT KOmice from the FNC
group. Data from Figures 4F–4H are representative of results obtained from five or six mice in each group. Asterisks indicate p < 0.05.
(I) Total and mature SREBP-1c protein levels were measured by immunoblotting in the livers of L-ARNT KOmice from the MNC group. Each lane represents the
liver protein extract from an individual mouse. Data are representative of results obtained from 3–6 mice in each group. Asterisks indicate p < 0.05.Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc. 435
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Function of ARNT in LiverFigure 5. Effects of L-ARNT KO on Hepatic Fatty Acid b-Oxidation and Ketogenesis
(A) Fed serum b-hydroxybutyrate (b-OHB) levels in Control and L-ARNT KO mice from the FNC, MNC, and FHF groups.
(B) Fasting serum b-OHB levels in Control and L-ARNT KO mice from the MNC group.
(C) Total and phosphorylation levels of AMPK and ACC1 proteins were measured by western blotting in the livers of Control and L-ARNT KO mice from the FNC
and MNC groups.
(D) Quantification of protein ratio of p-AMPK/AMPK and p-ACC/ACC in the livers of Control and L-ARNT KO mice from the FNC and MNC groups.
(E) Malonyl-CoA levels in Control and L-ARNT KO mice from the FNC and MNC groups.
(F) mRNA levels of FGF21 genes in the livers of Control and L-ARNTKOmice from theMNC group. Data are representative of results obtained from five or sixmice
in each group. Asterisks indicate p < 0.05.Recently, studies from two laboratories have shown that
growth factor FGF21 is involved in control of ketone body forma-
tion and that FGF21 transgenic mice exhibit increased ketogen-
esis (Inagaki et al., 2007; Badman et al., 2007). While FGF21
mRNA levels were detected in liver of L-ARNT mice, there was
no significant change in the expression of FGF21 gene in these
livers compared with Control (Figure 5F).
DISCUSSION
In this study, we have shown that there is a reduction in expres-
sion of ARNT in livers of humans with type 2 diabetes. When
the effect of this reduction of ARNTwas assessed by acute abla-436 Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc.tion of the ARNT gene in the liver of mice, we found an increase in
gluconeogenesis and lipogenesis, an increase in serum insulin
levels, and a relative decrease in ketogenesis. These findings in
L-ARNT KO mice mimic those of human type 2 diabetes,
suggesting that a deficiency of ARNT action in the liver could
contribute to the altered metabolic function in humans with
type 2 diabetes. In previous studies, we have shown that individ-
uals with type 2 diabetes have a marked reduction of ARNT
expression in pancreatic islets, which when modeled in cells
and mice leads to impaired glucose-stimulated insulin secretion
and glucose intolerance (Gunton et al., 2005). Taken together,
these results suggest that reductions in ARNT expression in the
b cell and liver may play important roles in the defects observed
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Function of ARNT in Liverin human type 2 diabetes in glucose homeostasis and lipid
metabolism.
The effects of reduction in ARNT on hepatic gluconeogenesis
and lipogenesis are mediated by elevated expression of key glu-
coneogenic and lipogenic enzymes, including PEPCK, G6Pase,
SCD1, and FAS. Studies from multiple research groups have
shown that the rate-limiting enzymes involved in gluconeogen-
esis and lipogenesis are mainly regulated at the transcriptional
level by a number of transcription factors and their coregulators
(Pedersen et al., 2007;Qiao et al., 2006; Sinal et al., 2000; Foufelle
and Ferre, 2002; Horton et al., 2002; Puigserver et al., 2003; Yoon
et al., 2001). C/EBPa is essential for the activation of hepatic
glucose production at birth, and disruption of the C/EBPa gene
in mice causes hypoglycemia associated with the impaired
expression of the gluconeogenic enzymes PEPCK and G6Pase
(Pedersen et al., 2007; Qiao et al., 2006). Acute knockout of
C/EBPa also significantly reduces the expression of lipogenic
genes, including ACC, SCD1, and FAS (Pedersen et al., 2007;
Qiao et al., 2006). These effects occur through C/EBPa binding
to its binding element on these gene promoters (Pedersen
et al., 2007; Schmoll et al., 1999). ARNT appears to function as
an upstream regulator of C/EBPa, such that knockout of ARNT
increases C/EBPa gene expression, which in turn activates the
expression of gluconeogenic and lipogenic enzymes.
Besides the increase in C/EBPa gene expression, acute
knockout of ARNT also increases the expression of FXR and
SREBP-1c, two important regulators of lipid homeostasis (Sinal
et al., 2000; Foufelle and Ferre, 2002; Horton et al., 2002).
SREBP-1c mRNA is the predominant isoform in liver and is
a member of the bHLH family of DNA binding proteins that
form dimers that recognize the inverted E-box repeats.
SREBP-1c mRNA expression is controlled in part by insulin,
increased by a fasting and refeeding regimen, and decreased
in rats with STZ-induced diabetes. Overexpression of SREBP-
1c in liver prevented the downregulation of lipogenic genes
Figure 6. A Possible Model of ARNT Reduction in Liver
ARNT reduction in liver increases fed insulin levels and
elevates hepatic gluconeogenesis. In parallel, expression of
key gluconeogenic enzymes, such as PEPCK, G6Pase, and
FBP1, is increased. ARNT reduction in liver also changes
hepatic lipid size and activation of lipogenesis process,
possibly due to elevated expression of genes encoding FXR,
SREBP-1c, FAS, and SCD1.
during fasting via upregulation of the genes control-
ling fatty acid synthesis (Jump et al., 2005). Thus,
acute knockout of ARNT activates the expression
of C/EBPa and SREBP-1c genes. Identifying
ARNT as an upstream regulator of SREBP-1c and
C/EBPa genes may cast some light on the regula-
tion of glucose and lipid homeostasis in the liver.
Insulin signaling plays an important role in the
regulation of hepatic glucose homeostasis (Saltiel
and Kahn, 2001; Michael et al., 2000). Mice with
liver-specific insulin receptor knockout (LIRKO)
exhibit dramatic insulin resistance, severe glucose
intolerance, and a failure of insulin to suppress
hepatic glucose production due to increased
PEPCK and G6Pase gene expression (Michael et al., 2000).
Interestingly, L-ARNT KO mice exhibit a similar but milder
phenotype compared to LIRKOmice with unsuppressed hepatic
gluconeogenesis and hyperinsulinemia. LIRKO mice, however,
exhibit reduced expression of SREBP-1c and FXR (Biddinger
et al., 2008), which clearly distinguishes them from the L-ARNT
KO mice and points to different forms of hepatic insulin resis-
tance created by these two pathways.
L-ARNT KO mice also exhibit hypoketonemia, a feature not
observed in LIRKO mice. It is believed that anabolic effects of
the relatively high insulin concentrations in type 2 diabetes cause
reduced fatty acid b-oxidation in the liver, which prevents the
formation of ketone bodies. The hypoketonemia in L-ARNT
mice could, therefore, be due in part to the hyperinsulinemia of
these mice. AMP-activated protein kinase (AMPK) is the primary
regulator of the cellular response to reduced ATP levels and may
also play a role in the reduced ketogenesis (Ruderman et al.,
2003; Musi, 2006; Assifi et al., 2005). AMPK is an important
metabolic switch, phosphorylating key target proteins that lead
to stimulation of hepatic fatty acid oxidation and ketogenesis,
inhibition of cholesterol synthesis, lipogenesis, and TG synthesis
(Ruderman et al., 2003; Musi, 2006; Assifi et al., 2005). Phos-
phorylation of AMPK was reduced in L-ARNT KO mice, which
could contribute to reduced fatty acid oxidation and reduced
formation of ketone bodies while allowing increased function of
the enzymes in the lipogenic pathway. Recent studies have
shown that FGF21 is involved in control of ketone body formation
(Inagaki et al., 2007; Badman et al., 2007). Mice on a ketogenic
diet have increased FGF21 expression, and FGF21 transgenic
mice exhibit increased ketogenesis. However, there was no
change in the expression of FGF21 gene in L-ARNT KO mice
compared to control. Thus it appears likely that the reduced
formation of b-OHB in L-ARNT KO mice is the product of the
anabolic effects of hyperinsulinemia and the reduction of phos-
phorylation of AMPK.Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc. 437
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Function of ARNT in LiverOne of the most interesting findings in the L-ARNT KO mice
was the reduced size of the lipid droplets in their livers. It is
known that lack of PAT family proteins reduces the size of lipid
droplets (Londos et al., 2005). L-ARNT mice have a trend to
reduced levels of ADRP, one of the PAT proteins, in their livers,
which may contribute to the reduced size of the lipid droplets,
although this effect is very modest.
The exact molecular mechanism of ARNT action on hepatic
metabolism may be complex. ARNT is a member of the bHLH/
PAS family of proteins (Reisz-Porszasz et al., 1994). ARNT func-
tions through heterodimerization with AHR in the toxic effect of
dioxin. Within the nucleus, AHR/ARNT heterodimers bind to
specific DNA response elements with the consensus motif
TNGTGTG of the target promoter to control gene transcription.
The other dimerization partners of ARNT include SIM1 and
SIM2 (regulators of neurogenesis) and HIF1a and HIF2a (regula-
tors of the cellular response to hypoxia) (Semenza, 1999; Ema
et al., 1997). Thus, ARNT may play a role in regulating many
different signaling pathways by partnering with different tran-
scription factors. Studies on overexpression of ARNT partners
are needed to gain more insight into the mechanisms of ARNT
action in the liver.
Themetabolic syndrome shares a number of features of type 2
diabetes and is also increasing at an alarming rate, with almost
25% of the adult U.S. population currently affected. Given the
fact that the metabolic syndrome and type 2 diabetes increase
the risk of many other conditions, including nonalcoholic fatty
liver and cardiovascular disease, more specific and effective
therapeutic strategies are urgently needed. Certain ligand-acti-
vated nuclear receptors, including FXR, SREBP-1c, and C/
EBPa, provide promising new targets for this purpose. Since
ARNT/HIF1b acts as an upstream regulator of FXR, SREBP-1c,
and C/EBPa genes in the regulation of insulin-mediated inhibi-
tion on gluconeogenesis and lipogenesis (Figure 6), approaches
to modulate ARNT levels or its transcriptional effects could
provide a novel approach for treatment of diabetes, fatty liver,
and the metabolic syndrome.
EXPERIMENTAL PROCEDURES
Animals, Adenoviruses, and Plasma/Serum
Biochemical Measurements
ARNT flox/flox mice were generated as previously described (Tomita et al.,
2000). Three groups of ARNT flox/flox mice were studied: male and female
mice (9–11 months) on normal chow diet (MNC and FNC, respectively) and
female mice (9 months) that had been on a 60% high-fat diet for 3 months
(FHF). In each group, half of the mice were injected with the adenoviral-Cre
construct and half with a control adenovirus via the tail vein 4–6 days prior
to the experiments.
Glucose Tolerance and Pyruvate Challenge Tests
For GTT, ARNT flox/flox and L-ARNT KO mice deprived of food for 16 hr were
injected intraperitoneally (i.p.) with glucose (2 g/kg body weight), and glucose
from tail vein blood was measured at 0–120 min using a glucometer. For the
pyruvate challenge test, 16 hr fasted mice were injected i.p. with pyruvate
(2 g/kg) dissolved in saline, and glucose was measured as above.
Hyperinsulinemic-Euglycemic Clamp Experiments
The jugular vein of ARNT flox/flox mice was cannulated. After a 2 day recovery
period, Cre and control adenovirus were injected. After an additional 5 days
and a 4 hr fast, a hyperinsulinemic-euglycemic clamp was performed with
D-[3-3H]glucose as described by Norris et al., 2003, using a continuous insulin438 Cell Metabolism 9, 428–439, May 6, 2009 ª2009 Elsevier Inc.infusion of 3.5 mU/kg/min. The adenoviral injection and the clamp technique
were carried out without knowledge, i.e., blinded of the genotype until all
calculations were completed. Hepatic glucose production was assessed by
subtraction of the glucose infusion rate from whole-body glucose turnover
as measured with D-[3-3H]glucose.
Hepatic De Novo Lipogenesis
ARNT flox/flox and L-ARNT KOmice were injected with 0.5mCi of 3H2O (0.4ml
of 1.25 mCi/ml). The rate of hepatic de novo lipogenesis was determined
by measuring the amount of newly synthesized FA and TG present in the liver
1 hr after the i.p. injection. 3H-labeled fatty acids were isolated by saponifica-
tion of liver samples in KOH. After extraction of nonsaponifiable lipids and
acidification with H2SO4, the
3H-labeled fatty acids were extracted with chlo-
roform and separated by thin layer chromatography. The plate was stained
with primulin. The FA and TG spots were scraped off the plate, added to
scintillation fluid, and counted in a liquid scintillation counter. The specific
activity of body water was determined and used to calculate de novo lipogen-
esis as micromoles of 3H2O incorporated into FA/hr/g and TG/hr/g of liver
tissue.
Quantification of Hepatic Malonyl-CoA and TG Contents
Liver tissues were removed from ARNT flox/flox and L-ARNT KO mice and
immediately frozen in liquid nitrogen. Liver was homogenized and deprotei-
nized with 10% perchloric acid, the filtrate was neutralized (Saha et al.,
1997), and malonyl CoA was determined radioenzymatically by a modification
of the method of McGarry (McGarry et al., 1978). For the measurement of
hepatic TG content, 0.1–0.2 g of liver tissue from each mouse was homoge-
nized in 500 ml buffer containing 150 mM NaCl and 10 mM Tris (pH 7.5) and
extracted with 400 ml methanol and 800 ml chloroform. The chloroform layer,
containing TG, was evaporated overnight and resuspended in 70% ethanol;
TG was measured enzymatically and expressed relative to protein content.
Statistics
The results are expressed as means ± SEM. Significance was established
using the Student’s t test and analysis of variance when appropriate. Differ-
ences were considered significant at p < 0.05. Two-way ANOVA with repeat
measurements was performed to analyze measurements obtained by time
course.
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